| dc.contributor.author | Mulubwa, Mwila | |
| dc.contributor.author | Mugabo, Pierre | |
| dc.date.accessioned | 2023-02-08T09:56:21Z | |
| dc.date.available | 2023-02-08T09:56:21Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Mulubwa, M., & Mugabo, P. (2019). Steady‐state population pharmacokinetics of terizidone and itsmetabolite cycloserine in patients with drug‐resistanttuberculosis. British Journal of Clinical Pharmacology, 85 (9) , 1946-1956. https://doi.org/10.1111/bcp.13975 | en_US |
| dc.identifier.issn | 1365-2125 | |
| dc.identifier.uri | https://doi.org/10.1111/bcp.13975 | |
| dc.identifier.uri | http://hdl.handle.net/10566/8385 | |
| dc.description.abstract | Despite terizidone being part of the second‐line recommended drugs fortreatment of drug‐resistant tuberculosis (DR‐TB), information on its pharmacokineticsis scarce. The aim of this study was to describe the steady‐state population pharma-cokinetics (PPK) of terizidone and its primary metabolite cycloserine in patients withDR‐TB and determine the effect of patient characteristics. This clinical study involved 39 adult DR‐TB patients admitted toBrewelskloof Hospital in Cape Town, South Africa for intensive treatment phase.Blood samples were collected at predose and 0.5, 1, 2, 3, 3.5, 4, 8, 16 and 24 hoursafter drug administration. The estimation of PPK parameters was performed usingnonlinear mixed‐effects modelling software Monolix 2018R1. Free‐fat mass was usedto perform allometric scaling on disposition parameters. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley | en_US |
| dc.subject | Cycloserine | en_US |
| dc.subject | Tuberculosis | en_US |
| dc.subject | Pharmacokinetics | en_US |
| dc.subject | Patients | en_US |
| dc.subject | Pharmacology | en_US |
| dc.title | Steady‐state population pharmacokinetics of terizidone and itsmetabolite cycloserine in patients with drug‐resistanttuberculosis | en_US |
| dc.type | Article | en_US |
